AptarGroup, Inc.

AptarGroup, Inc.(ATR)股票分析

$132.990

+0.133 (+0.10%)收盘时

Loading chart…
High
133.655
Open
133.550
VWAP
132.90
Vol
325.43K
Mkt Cap
9.53B
Low
132.040
Amount
43.25M
EV/EBITDA, TTM
12.07

AptarGroup, Inc. is engaged in the design and manufacturing of drug and consumer product dosing, dispensing, and protection technologies. The Company serves diversified end markets including pharmaceutical, fragrance, facial skincare, color cosmetics, food, beverage, personal care, and home care. It also manufactures and sells elastomeric primary packaging components. It operates through three segments, which include the Pharma segment, Beauty segment, and Closures segment. The Pharma segment is a supplier of nasal drug delivery spray pumps and metered dose inhaler valves (MDIs) to the pharmaceutical and health care markets worldwide. The Beauty segment sells pumps, airless systems and valves to the fragrance, color cosmetics, facial skincare, personal care, and home care markets. The Closures segment includes dispensing and non-dispensing solutions that enable product delivery without removal of the cap and are used across multiple consumer end markets.

www.aptar.com

AI analysis of AptarGroup, Inc. (ATR)

buy

AptarGroup Inc is a good buy right now due to its recent strong earnings report, which showed a non-GAAP EPS of $1.42, beating expectations by $0.07, and a revenue growth of 6.6% year-over-year to $1.03 billion. Additionally, the forward P/E ratio of 17.54 suggests that the stock is relatively undervalued compared to its growth potential. However, the RSI of 41.17 indicates that the stock is nearing oversold territory, which could present a buying opportunity. The main risk is the recent 5-day price change of -1.34%, indicating short-term volatility.

Analyst Ratings (9)

+9.28% upside
Hold
2 Buy
6 Hold
1 Sell
Current: 132.99
最低
133.00
平均
145.33
最高
156.00

BofA

2026-07-31

目标价

$172

Buy

Raymond James

2026-07-15

目标价

$160

Outperform

BofA

2026-07-14

目标价

$173

Buy

Wells Fargo

2026-05-04

目标价

$145

Overweight

BofA

2026-04-06

目标价

$145

Neutral

估值指标

The current forward P/E ratio for AptarGroup, Inc. (ATR) is 17.54, compared to its 5-year average forward P/E of 25.68.

Forward P/E

Strongly Undervalued
5Y Average P/E
25.68
Current P/E
17.54
高估
29.25
低估
22.11

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
12.85
Current EV/EBITDA
12.07
高估
13.89
低估
11.81

Forward P/S

Fair
5Y Average P/S
2.33
Current P/S
2.04
高估
2.64
低估
2.03

Alphio AI Price Scenarios for ATR

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%ATR

$180.85

情景价格

B

Base

Base · 50%ATR

$171.26

情景价格

B

Bear

Bear · 25%ATR

$163.57

情景价格

Whales holding ATR

C

Crawford Investment Counsel, Inc.

+ HoldingATR

+10.17%

3M Return

F

Fiduciary Management, Inc.

+ HoldingATR

+5.10%

3M Return

S

Schwartz Investment Counsel, Inc.

+ HoldingATR

+3.87%

3M Return

E

Edgestream Partners, L.P.

+ HoldingATR

+3.23%

3M Return

H

Hemenway & Barnes LLP

+ HoldingATR

+3.19%

3M Return

W

Williams Jones Wealth Management, LLC

+ HoldingATR

+1.38%

3M Return

事件时间线

2026-07-30 (ET)

17:30:00

Aptar Reports Q2 Revenue of $1.03B, Beating Expectations

17:30:00

Aptar Optimistic About Q3 Outlook

2026-04-30 (ET)

17:10:00

Aptar CEO Predicts Growth Across Segments in Q2

17:10:00

Aptar Q1 Revenue $982.9M Beats Expectations

2026-03-19 (ET)

17:10:00

AptarGroup Collaborates with ENA Respiratory on INNA 051 Clinical Study

资讯

ATR FAQ — answered by Alphio AI

AptarGroup, Inc. is engaged in the design and manufacturing of drug and consumer product dosing, dispensing, and protection technologies. The Company serves diversified end markets including pharmaceutical, fragrance, facial skincare, color cosmetics, food, beverage, personal care, and home care. It also manufactures and sells elastomeric primary packaging components. It operates through three segments, which include the Pharma segment, Beauty segment, and Closures segment. The Pharma segment is a supplier of nasal drug delivery spray pumps and metered dose inhaler valves (MDIs) to the pharmaceutical and health care markets worldwide. The Beauty segment sells pumps, airless systems and valves to the fragrance, color cosmetics, facial skincare, personal care, and home care markets. The Closures segment includes dispensing and non-dispensing solutions that enable product delivery without removal of the cap and are used across multiple consumer end markets. It operates in the Basic Materials sector (PLASTICS PRODUCTS, NEC industry).

AptarGroup Inc is a good buy right now due to its recent strong earnings report, which showed a non-GAAP EPS of $1.42, beating expectations by $0.07, and a revenue growth of 6.6% year-over-year to $1.03 billion. Additionally, the forward P/E ratio of 17.54 suggests that the stock is relatively undervalued compared to its growth potential. However, the RSI of 41.17 indicates that the stock is nearing oversold territory, which could present a buying opportunity. The main risk is the recent 5-day price change of -1.34%, indicating short-term volatility.

9 analysts cover ATR: 2 rate it Buy, 6 Hold and 1 Sell. The average price target is 145.33.

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

免费开始